Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme
Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...
Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare
Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...
Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...
Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2
Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
Koutech Robotics Secures Series A Funding for Surgical Innovation
China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...
Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...
Beijing Designates 923 Medical Entities for National Reimbursement Drug List
The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...
Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...
Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China
China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...
Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...
WuXi Biologics Partners with Elpiscience for Macromolecule Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...
Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...
RemeGen Announces Positive Phase III Results for Telitacicept in SLE
China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...
Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia
Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...
Beijing Launches HIV Precision Medicine Standardization Project
On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...